Lilly’s Bydureon falls short of competitor in study
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
Health Care Businesses
UPDATE: Bioanalytical researcher opening lab in Indianapolis
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
UPDATE: Lilly settles pollution suit for $337,500
A complaint filed Wednesday by the U.S. government says Lilly’s plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
Eli Lilly neuroscience chief resigns
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
Lilly takeover provision to be voted on again
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the company’s April 18 annual meeting.
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Health insurers expect hit from reform rule
Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.
Lilly collaboration with outside researchers yields first deal
Eli Lilly and Co.’s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it’s just the first of many such collaborations.
2010 compensation fell about 20 percent for top Lilly execs
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Head of Lilly’s oncology unit resigning
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
Vanderbilt rejected by high court on Cialis patents
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.
Lilly seeks to block imports of cancer drug copy
The local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent on the process for making the active ingredient.
Lilly imaging drug fails to win FDA panel’s backing
Eli Lilly and Co.’s Amyvid isn’t ready to be approved to detect Alzheimer’s-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Lilly imaging drug isn’t ready for approval, FDA says
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer’s disease isn’t ready for approval, according to U.S. regulators.
Roche back in court as partner looks to sell to competitor
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
Closed dental company working to transfer patients
Citing cash-flow problems, Allcare Dental and Dentures shut down operations in 14 states, including Indiana, last week.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.